MALAKOFF, France--(BUSINESS WIRE)--Regulatory News:
THERACLION (Paris:ALTHE) (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, announces today that the Bürgerhospital (Frankfurt, Germany) has signed a commercial agreement for the treatment of thyroid nodules with Echopulse. For the first time the system will be utilized in a surgical department for this indication.
The Bürgerhospital Frankfurt is a clinic featuring an endocrine surgery center of excellence. It is one of a few centers of reference for endocrine surgery certified by the DGAV (German society for general and visceral surgery). Within this context they are responsible for continued education of other German endocrine surgical centers and are on the forefront of clinical development and deployment of innovation.
In the Bürgerhospital around 1,400 thyroid surgeries are performed annually. The center provides its patients with all available operating techniques as well as innovative techniques such as elastography by ultrasound on the diagnostics side, a technique which helps to assess the benignity of a nodule non-invasively. It will now also offer Echopulse for the treatment of benign thyroid nodules requiring or desiring a non-invasive alternative.
“In a first step, we are evaluating the system’s performance in a 6 months rental phase whilst creating a registry and collecting clinical outcomes in a controlled study. We are convinced that the treatment will benefit our patients and give a new direction to the treatment of thyroid nodules in Germany,” says Dr. Christian Vorländer, head of the endocrine surgery department of the Bürgerhospital.
“Working with one of the best endrocrine surgery departments in Germany is extremely valuable for Theraclion. I’m very much looking forward to this collaboration,” adds Jose Abellan, VP Germany for Theraclion.
“I am excited about this commercial expansion into the largest European segment, the German thyroid market,” says David Caumartin CEO of Theraclion, “This confirms our strategic choice of focusing on Germany and leveraging the large need of the thyroid market. Dr. Vorländer is a commercial partner of high international standing. Our collaboration is a critical step in our mission to enlarge the role of echotherapy in clinical care.”
About Theraclion
Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.
Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 30 people, 53 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.
Theraclion is listed on Alternext Paris
PEA-PME Eligible
Mnemonic:
ALTHE - ISIN Code: FR0010120402